According to Zacks, “Ra Medical Systems, Inc. is a commercial-stage medical device company. It develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company’s product pipeline consists of DABRA which is a minimally-invasive excimer laser and disposable catheter system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease, or above- and below-the-knee. Pharos Excimer Laser is a powerful 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma. Ra Medical Systems, Inc. is based in Carlsbad, California. “
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Ra Medical Systems in a research report on Friday, February 18th.
Ra Medical Systems (NYSE:RMED – Get Rating) last issued its earnings results on Wednesday, March 23rd. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.59). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.70 million. Ra Medical Systems had a negative return on equity of 152.46% and a negative net margin of 2,278.22%. Equities analysts predict that Ra Medical Systems will post -1.7 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in RMED. Virtu Financial LLC increased its stake in shares of Ra Medical Systems by 632.2% in the 1st quarter. Virtu Financial LLC now owns 193,677 shares of the company’s stock valued at $77,000 after purchasing an additional 167,227 shares in the last quarter. UBS Group AG purchased a new position in shares of Ra Medical Systems in the 1st quarter valued at about $27,000. Vanguard Group Inc. increased its stake in shares of Ra Medical Systems by 125.8% in the 1st quarter. Vanguard Group Inc. now owns 338,495 shares of the company’s stock valued at $136,000 after purchasing an additional 188,608 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Ra Medical Systems in the 4th quarter valued at about $229,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Ra Medical Systems in the 3rd quarter valued at about $84,000. 2.82% of the stock is currently owned by institutional investors.
About Ra Medical Systems (Get Rating)
Ra Medical Systems, Inc, a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
- Get a free copy of the StockNews.com research report on Ra Medical Systems (RMED)
- Dentsply Stock is Repricing Itself
- Is Zoom Video (NASDAQ: ZM) Starting To Bottom Out?
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.